ArticleVaccines2025

Integrated In Silico and In Vivo Evaluation of a Tetravalent SARS-CoV-2 RBD-Fc Fusion Vaccine with Broad Cross-Variant Antibody Responses.

Ahmad Bakur Mahmoud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.